Obermatt

Insulet

NSQ:PODD · US45784P1012
Health Care Equipment & SuppliesLarge

360

71
EV / EBIT33
Price / Owner Earnings17
Owner Earnings Yield34
Dividend Yield1
Price/Sales50
EV / Gross Profit48
Price/Book28
Return on Capital87
Cash Return on Capital76
Return on Equity85
EBIT Margin65
Gross Profitability99
Cash Conversion67
Accruals73
Owner Earnings Margin40
Sales growth80
Profit Growth82
Long-Term EPS Growth89
Owner Earnings Growth41
Reinvestment18
Price momentum14
Debt load43
Refinancing54
Debt Payback45
Liquidity73
Analyst ratings56
Opinion Changes69
Price Target Upside98
Market mood74
Value Creation14/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Insulet generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryHealth Care Equipment & Supplies
SizeLarge
TypePublic Company
ExchangeNASDAQGS
Founded2000
Employees4,266
ISINUS45784P1012
Last UpdateApr 2, 2026
Themes
Machine LearningDiabetesCloud StorageWearablesHealth CareMedicalMedical Device

Description

Insulet Corporation engages in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod 5 Automated Insulin Delivery System (…

Analysis

Quality compounder

Insulet Corporation is a quality compounder: a well-run business trading at a price that reflects what it is worth.

The price is expensive. You pay 53.1× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 19% yearly growth; analysts expect 21%. The price, in other words, assumes less than the experts do.

The trajectory is solid and the balance sheet is adequate. The company scores 14/20 on our value-creation score: strong value creator.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
57
2023202420252026

All-time high

57

Jun 2026

All-time low

10

Jan 2023

Average rank

37

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
50
11
18
9
Price/Earnings
29
9
19
10
Price/Book
28
8
1
7
Dividend Yield
1
1
1
1
Value (overall)
20
1
4
1

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Insulet with its peers
Tandem Diabetes
NMQ:TNDM
34
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeMedium
Full Stock Analysis →
KORU Medical Systems
NAQ:KRMD
40
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
SS Innovations International
NAQ:SSII
26
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Dexcom
NSQ:DXCM
92
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeX-Large
Full Stock Analysis →
Artivion
NYQ:AORT
49
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeMedium
Full Stock Analysis →
Pulse Biosciences
NAQ:PLSE
45
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →